HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 3, 2011, Pages 143-146

  Sezgin, Ezgi ^a   Sahin, Feride Iffet ^a   Yagmurdur, Mahmut Can ^a   Demirhan, Beyhan ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; VALINE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RISK; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; FEMALE; GENES, ERBB-2; GENOTYPE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 79952132921     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0126     Document Type: Article

References (16)

1. Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260-263. (Pubitemid 38569788)
2. Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular- activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 99:15937-15940. (Pubitemid 35462727)
3. Goksel HA, Yagmurdur MC, Karakayali H, et al. (2004) Management of bilateral breast carcinoma: long-term results. Int Surg 89:166-171. (Pubitemid 39430429)
4. Harari D, Yarden Y (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114. (Pubitemid 32059460)
5. Hudelist G, Singer CF, Manavi M, et al. (2003) Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80:353-361. (Pubitemid 37046760)
6. Kamali-Sarvestani E, Talei AR, Merat A (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83-87. (Pubitemid 39221462)
7. Keshava C, Mccanlies EC, Keshava N, et al. (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37-41. (Pubitemid 32907507)
8. Kuraoka K, Matsumura S, Hamai Y, et al. (2003) A single nucleotide polymorphism in the transmembrane domain coding region of Her-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 107:593-596. (Pubitemid 37296120)
9. Lee SC, Hou MF, Hsieh PC, et al. (2008) A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 41:121-125.
10. Mcpherson K, Steel CM, Dixon JM (2000) Breast cancer epidemiology, risk factors and genetics. BMJ 321:624-628.
11. Millikan R, Eaton A, Worley K, et al. (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79:355-364. (Pubitemid 36750943)
12. Montgomery KG, Gertig D, Baxte, et al. (2003) The HER2 I655V polymorphism and risk of breast cancer in women (Pubitemid 37310272)
13. Rakha EA, El-Sayed ME, Lee AH, et al. (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153-3158.
14. Tao W, Wang C, Han R, et al. (2009) HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 114:371-376.
15. Wang-Gohrke S, Chang-Claude J (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657-1659. (Pubitemid 33094876)
16. Xie D, Shu XO, Deng Z, et al. (2000) Population-based, case- control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417. (Pubitemid 30154823)